Department of Clinical and Biological Sciences, University of Torino, Italy.
Curr Med Chem. 2013;20(4):502-26. doi: 10.2174/0929867311320040003.
Due to the persistent lack of suitable vaccines, chemotherapy remains the only option for the treatment of patients infected by protozoan parasites. However, most available antiparasitic drugs have serious disadvantages, ranging from high cost and poor compliance to high toxicity and rapid induction of resistance. In recent decades basic research laboratories identified a considerable number of promising new molecules, but their development has not been pursued in depth by pharmaceutical firms because of poor prospects of economic return. The establishment of adequately funded public-private partnerships is currently reversing the trend. This review deals with new drugs against Plasmodium, Leishmania and Trypanosoma parasites, focusing on the molecules that are in the most advanced stage of development. The purpose of this article is to provide the reader with a panoramic view of the updated literature on the challenges and strategies of contemporary antiprotozoal drug research, paying the due attention to the already published reviews.
由于一直缺乏合适的疫苗，化疗仍然是治疗原生动物寄生虫感染患者的唯一选择。然而，大多数现有的抗寄生虫药物都存在严重的缺点，从高成本和低顺应性到高毒性和快速诱导耐药性不等。近几十年来，基础研究实验室已经发现了相当数量有前途的新分子，但由于经济回报前景不佳，制药公司并没有深入开发这些分子。目前，建立有充足资金的公私合作伙伴关系正在扭转这一趋势。这篇综述涉及针对疟原虫、利什曼原虫和锥虫寄生虫的新药，重点介绍处于开发最先进阶段的分子。本文的目的是为读者提供当代抗原生动物药物研究的挑战和策略的最新文献综述，同时适当关注已经发表的综述。
